Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies, Pediatrics, vol.136, pp.203-217, 2015. ,
Pediatric vascular malformations: pathophysiology, diagnosis, and the role of interventional radiology, Cardiovasc Intervent Radiol, vol.34, pp.691-704, 2011. ,
Lymphatic vascular morphogenesis in development, physiology, and disease, J Cell Biol, vol.193, pp.607-625, 2011. ,
Vascular malformations: classification and terminology the radiologist needs to know, Semin Roentgenol, vol.47, pp.106-123, 2012. ,
Molecular genetics of the PI3K-AKTmTOR pathway in genodermatoses: diagnostic implications and treatment opportunities, J Invest Dermatol, vol.136, pp.15-23, 2016. ,
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum, Am J Med Genet A, vol.164, pp.1713-1746, 2014. ,
Head and neck lymphatic malformation treatment: a systematic review, Otolaryngol Head Neck Surg, vol.147, pp.627-666, 2012. ,
Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial, Arch Otolaryngol Head Neck Surg, vol.128, pp.1137-1181, 2002. ,
Sirolimus in pediatric renal transplantation, Pediatr Transplant, vol.15, pp.673-85, 2011. ,
Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis, Cancer Sci, vol.98, pp.726-759, 2007. ,
Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase, Arterioscler Thromb Vasc Biol, vol.29, pp.1172-1180, 2009. ,
Sirolimus for the treatment of complicated vascular anomalies in children, Pediatr Blood Cancer, vol.57, pp.1018-1042, 2011. ,
Blue rubber bleb nevus syndrome: successful treatment with sirolimus, Pediatrics, vol.129, pp.1080-1084, 2012. ,
Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: asystematic review, Acta Derm Venereol, vol.96, pp.448-52, 2016. ,
Efficacy and safety of Sirolimus in the treatment of complicated vascular anomalies, Pediatrics, vol.137, issue.2, 2016. ,
The randomized placebo-phase design for clinical trials, J Clin Epidemiol, vol.54, pp.550-557, 2001. ,
A generalization of the «lady-tasting-tea» procedure to link qualitative and quantitative approaches in psychiatric research, Int J Stat Med Res, vol.2, pp.88-93, 2013. ,
Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use, Clin Exp Dermatol, vol.19, pp.210-216, 1994. ,
Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy, Pediatr Dermatol, vol.30, pp.549-53, 2013. ,
Propranolol for intractable diffuse lymphangiomatosis, N Engl J Med, vol.364, pp.1380-1382, 2011. ,
Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF, PLoS One, vol.7, p.42913, 2012. ,
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor, Proc Natl Acad Sci U S A, vol.96, pp.8663-8671, 1999. ,
Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression, Mol Cell Biol, vol.19, pp.2032-2075, 1999. ,
Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB, Hum Mol Genet, vol.22, pp.3438-3486, 2013. ,
, Law 2002-303 on patients' rights and information, 2017.